Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-22 DOI:10.1080/17474124.2024.2412045

Juan Deng, Dongmei Deng, Bing Wang, Valentina Donati, Adam E Frampton, Elisa Giovannetti

{"title":"Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer.","authors":"Juan Deng, Dongmei Deng, Bing Wang, Valentina Donati, Adam E Frampton, Elisa Giovannetti","doi":"10.1080/17474124.2024.2412045","DOIUrl":null,"url":null,"abstract":"Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of tumor-related deaths. The gut microbiota has gained attention in cancer treatment, due to its influence on the immune system and drug activity.Areas covered: Tintelnot and collaborators highlight distinct gut microbiota composition in metastatic PDAC (mPDAC) patients responding versus non-responding to chemotherapy. In the context of chemotherapy treatment, the gut microbiota of responders can metabolize tryptophan from food into indole-3-acetic acid (3-IAA). The presence of neutrophil-derived myeloperoxidase facilitates the role of 3-IAA in promoting the accumulation of reactive oxygen species in tumor cells. This accumulation, in turn, inducing tumor cell cytotoxicity. Additionally, 3-IAA can inhibit tumor cell autophagy activity, diminishing tumor cells' ability to adapt to cell stress. This manuscript provides a comprehensive analysis of the latest research on microbiota, metabolites, and PDAC, sourced from PubMed, ScienceDirect, and Google Scholar.Expert opinion: The evaluated study noted an elevation of the bacterial metabolite 3-IAA in responsive PDAC patients' serum, suggesting its potential to enhance chemotherapy sensitivity. Gaining a thorough comprehension of the impact of gut microbiota metabolites on drug activity is beneficial for broadening our strategies to mitigate chemotherapy resistance in tumors and identifying markers that predict chemotherapy outcomes.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"597-604"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2412045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of tumor-related deaths. The gut microbiota has gained attention in cancer treatment, due to its influence on the immune system and drug activity.

Areas covered: Tintelnot and collaborators highlight distinct gut microbiota composition in metastatic PDAC (mPDAC) patients responding versus non-responding to chemotherapy. In the context of chemotherapy treatment, the gut microbiota of responders can metabolize tryptophan from food into indole-3-acetic acid (3-IAA). The presence of neutrophil-derived myeloperoxidase facilitates the role of 3-IAA in promoting the accumulation of reactive oxygen species in tumor cells. This accumulation, in turn, inducing tumor cell cytotoxicity. Additionally, 3-IAA can inhibit tumor cell autophagy activity, diminishing tumor cells' ability to adapt to cell stress. This manuscript provides a comprehensive analysis of the latest research on microbiota, metabolites, and PDAC, sourced from PubMed, ScienceDirect, and Google Scholar.

Expert opinion: The evaluated study noted an elevation of the bacterial metabolite 3-IAA in responsive PDAC patients' serum, suggesting its potential to enhance chemotherapy sensitivity. Gaining a thorough comprehension of the impact of gut microbiota metabolites on drug activity is beneficial for broadening our strategies to mitigate chemotherapy resistance in tumors and identifying markers that predict chemotherapy outcomes.

查看原文本刊更多论文

来自肠道微生物群的代谢物可减轻胰腺癌的化疗耐药性。

简介胰腺导管腺癌（PDAC）是导致肿瘤相关死亡的第三大原因。由于肠道微生物群对免疫系统和药物活性的影响，肠道微生物群在癌症治疗中备受关注：Tintelnot及其合作者强调了对化疗有反应和无反应的转移性肺转移癌（mPDAC）患者的不同肠道微生物群组成。在化疗过程中，应答者的肠道微生物群能将食物中的色氨酸代谢为吲哚-3-乙酸（3-IAA）。中性粒细胞衍生的髓过氧化物酶的存在促进了 3-IAA 在肿瘤细胞中活性氧的积累。这种积累反过来又会诱发肿瘤细胞的细胞毒性。此外，3-IAA 还能抑制肿瘤细胞的自噬活性，削弱肿瘤细胞适应细胞压力的能力。本手稿全面分析了有关微生物群、代谢物和 PDAC 的最新研究，资料来源包括 PubMed、ScienceDirect 和 Google Scholar：评估的研究注意到，有反应的PDAC患者血清中细菌代谢物3-IAA升高，这表明它有可能提高化疗敏感性。全面了解肠道微生物群代谢物对药物活性的影响有利于我们拓宽减轻肿瘤化疗耐药性的策略，并确定预测化疗结果的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.